Business News, In Brief
Executive Summary
Companies talk drug launches and pipelines during first quarter earnings calls in May; with some having more success than others.
You may also be interested in...
McKesson/Celesio Deal Targets Generics Purchasing Synergies
McKesson believes its acquisition of European drug wholesaler Celesio will result in $275 million to $325 million in synergies four years out, and much of the savings will be achieved through generic drug purchasing.
Ironwood/Forest Talk Ballpark Pricing For Linzess, Gear Up For Q4 Launch
Locally-acting linaclotide wins FDA approval for two indications – chronic idiopathic constipation and constipation-predominant irritable bowel syndrome – with no limits on length of use, a development that could reinvigorate the GI space.
IBS Trials Should Gauge Efficacy In Maintenance And Retreatment, FDA Says
Agency’s final guidance on clinical evaluation of irritable bowel syndrome drugs says sponsors should assess benefits of maintenance therapy and repeated courses of treatment in addition to short-term efficacy. The recommendations on clinical endpoints are “provisional” pending development of new patient-reported outcome measures.